Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Explorer Kit
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
OBD expands its biomarker discovery programme for ALS diagnosis.
January 15, 2016
|
In
Milestones
|
By
Catia Gaspar
Check out the news in International Pharmaceutical Industry (IPI)
Prev
Next
Privacy Preference Center
Privacy Preferences
